BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

...its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc....
...mid-year. The company is also seeking a development partner for the fibrosis program. COMPANY PROFILE Aluda Pharmaceuticals Inc....
...necrosis factor α VEGF - Vascular endothelial growth factor VIM - Vimentin Sandi Wong, Assistant Editor Vimentin (VIM) Aluda Pharmaceuticals Inc. ALD-R491...
Items per page:
1 - 1 of 1
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

...its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc....
...mid-year. The company is also seeking a development partner for the fibrosis program. COMPANY PROFILE Aluda Pharmaceuticals Inc....
...necrosis factor α VEGF - Vascular endothelial growth factor VIM - Vimentin Sandi Wong, Assistant Editor Vimentin (VIM) Aluda Pharmaceuticals Inc. ALD-R491...
Items per page:
1 - 1 of 1